BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond

Blog Article

Altering the natural history of acute myeloid kelley coures evansville leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort.The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date for older patients with AML.In this review, we will explain how and why VEN works, summarize its remarkable pathway to regulatory approval, and highlight the key milestones that have been important for its successful development in AML.We also provide perspectives on some of the challenges associated with using VEN in the clinic, emerging knowledge regarding mechanisms of treatment failure, and current clinical research directions likely to shape how this drug and others in this new class of anticancer agents are used pantaloni bianchi neonato in the future.